Workflow
质量控制仪器和一次性产品
icon
Search documents
Mettler-Toledo (MTD) Q2 Earnings and Revenues Top Estimates
ZACKS· 2025-07-31 22:46
Company Performance - Mettler-Toledo reported quarterly earnings of $10.09 per share, exceeding the Zacks Consensus Estimate of $9.58 per share, and showing an increase from $9.65 per share a year ago, representing an earnings surprise of +5.32% [1] - The company achieved revenues of $983.22 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.67% and increasing from $946.75 million year-over-year [2] - Over the last four quarters, Mettler-Toledo has consistently surpassed consensus EPS and revenue estimates [2] Stock Outlook - Mettler-Toledo shares have increased approximately 3.5% since the beginning of the year, while the S&P 500 has gained 8.2% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is $10.57, with expected revenues of $987.38 million, and for the current fiscal year, the EPS estimate is $41.55 on revenues of $3.93 billion [7] Industry Context - The Medical - Instruments industry, to which Mettler-Toledo belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]
Mesa Labs (MLAB) Q4 Earnings and Revenues Lag Estimates
ZACKS· 2025-05-28 14:16
Core Viewpoint - Mesa Labs reported quarterly earnings of $2.23 per share, missing the Zacks Consensus Estimate of $2.75 per share, and down from $2.77 per share a year ago [1][2] Financial Performance - The earnings surprise for the quarter was -18.91%, with the company previously expected to post earnings of $2.45 per share but actually reporting $2.67 per share in the prior quarter, resulting in a positive surprise of 8.98% [2] - Revenues for the quarter were $62.14 million, missing the Zacks Consensus Estimate by 1.53%, compared to $58.9 million in the same quarter last year [3] - Over the last four quarters, Mesa Labs has surpassed consensus revenue estimates two times [3] Stock Performance - Mesa Labs shares have declined approximately 14.2% since the beginning of the year, while the S&P 500 has gained 0.7% [4] - The current Zacks Rank for Mesa Labs is 3 (Hold), indicating expected performance in line with the market in the near future [7] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $2.80 on revenues of $61.3 million, and for the current fiscal year, it is $11.35 on revenues of $255.3 million [8] - The trend of estimate revisions for Mesa Labs is mixed, which may change following the recent earnings report [7] Industry Context - The Medical - Instruments industry, to which Mesa Labs belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [9]
Sensus Healthcare, Inc. (SRTS) Reports Q1 Loss, Tops Revenue Estimates
ZACKS· 2025-05-15 22:26
Sensus Healthcare, Inc. (SRTS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of $0.04. This compares to earnings of $0.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -500%. A quarter ago, it was expected that this company would post earnings of $0.10 per share when it actually produced earnings of $0.09, delivering a surprise of -10%.Over the last four quarters, the company has surpa ...
Steris (STE) Surpasses Q4 Earnings Estimates
ZACKS· 2025-05-14 22:45
分组1 - Steris reported quarterly earnings of $2.74 per share, exceeding the Zacks Consensus Estimate of $2.59 per share, and up from $2.41 per share a year ago, representing an earnings surprise of 5.79% [1][2] - The company posted revenues of $1.48 billion for the quarter ended March 2025, slightly missing the Zacks Consensus Estimate by 0.09%, and compared to $1.42 billion in the same quarter last year [2] - Over the last four quarters, Steris has surpassed consensus EPS estimates three times, but has only topped consensus revenue estimates once [2] 分组2 - Steris shares have increased approximately 12.5% since the beginning of the year, significantly outperforming the S&P 500's gain of 0.1% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to those expectations [4][6] - The current consensus EPS estimate for the upcoming quarter is $2.32 on revenues of $1.36 billion, and for the current fiscal year, it is $9.94 on revenues of $5.78 billion [7] 分组3 - The Medical - Instruments industry, to which Steris belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook for the sector [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]
ClearPoint Neuro, Inc. (CLPT) Reports Q1 Loss, Tops Revenue Estimates
ZACKS· 2025-05-13 22:35
分组1 - ClearPoint Neuro, Inc. reported a quarterly loss of $0.22 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.15, representing an earnings surprise of -46.67% [1] - The company posted revenues of $8.49 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 2.85%, and showing an increase from $7.64 million in the same quarter last year [2] - ClearPoint Neuro has surpassed consensus revenue estimates three times over the last four quarters, while it has only surpassed consensus EPS estimates once in the same period [2] 分组2 - The stock has underperformed the market, losing about 11.3% since the beginning of the year compared to the S&P 500's decline of -0.6% [3] - The current consensus EPS estimate for the coming quarter is -$0.16 on revenues of $9.2 million, and for the current fiscal year, it is -$0.62 on revenues of $38.95 million [7] - The Medical - Instruments industry, to which ClearPoint Neuro belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]